NCT03462342 2026-03-17
CAPRI
University of Pennsylvania
Phase 2 Completed
Clinical Trials
19 trialsNCT04090567 2026-03-05
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03801369 2026-02-25
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT04417062 2026-02-25
Olaparib With Ceralasertib in Recurrent Osteosarcoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04065269 2026-02-20
ATARI
Institute of Cancer Research, United Kingdom
Phase 2 Active not recruiting
NCT03579316 2026-02-18
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04699838 2026-01-02
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT06680050 2025-12-18
AUSTRAL
Mario Negri Institute for Pharmacological Research
Phase 2 Recruiting
NCT05582538 2025-08-24
ATRiBRAVE
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Recruiting
NCT03740893 2025-08-11
PHOENIX
Institute of Cancer Research, United Kingdom
Phase 2 Recruiting
NCT02664935 2025-05-21
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Active not recruiting
NCT03787680 2025-03-28
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT03833440 2024-05-03
PIONeeR
Assistance Publique Hopitaux De Marseille
Phase 2 Active not recruiting
NCT04298008 2024-04-19
AZD6738 Plus Durvalumab in Biliary Tract Cancer
Seoul National University Hospital
Phase 2 Recruiting
NCT04298021 2024-04-19
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
Seoul National University Hospital
Phase 2 Active not recruiting
NCT02576444 2022-12-28
OLAPCO
Yale University
Phase 2 Terminated
NCT03780608 2022-06-15
This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)
Samsung Medical Center
Phase 2 Unknown
NCT03428607 2021-02-18
Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]
Samsung Medical Center
Phase 2 Completed
NCT03182634 2019-01-22
plasmaMATCH
Institute of Cancer Research, United Kingdom
Phase 2 Unknown